AN2 Therapeutics (ANTX) Stock Forecast, Price Target & Predictions
ANTX Stock Forecast
AN2 Therapeutics stock forecast is as follows: an average price target of $8.75 (represents a 741.35% upside from ANTX’s last price of $1.04) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ANTX Price Target
ANTX Analyst Ratings
AN2 Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 03, 2024 | Joseph Schwartz | Leerink Partners | $5.00 | $2.13 | 134.74% | 380.77% |
May 16, 2024 | Liisa Bayko | Evercore ISI | $2.00 | $2.27 | -11.89% | 92.31% |
Apr 02, 2024 | Roy Buchanan | JMP Securities | $6.00 | $3.76 | 59.57% | 476.92% |
Nov 14, 2022 | - | Leerink Partners | $25.00 | $14.87 | 68.12% | 2303.85% |
Apr 19, 2022 | - | Evercore ISI | $25.00 | $14.00 | 78.57% | 2303.85% |
Apr 19, 2022 | - | Oppenheimer | $22.00 | $14.72 | 49.46% | 2015.38% |
AN2 Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 3 |
Avg Price Target | - | $5.00 | $4.33 |
Last Closing Price | $1.04 | $1.04 | $1.04 |
Upside/Downside | -100.00% | 380.77% | 316.35% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 09, 2024 | Evercore ISI | - | Underperform | Downgrade |
Jul 03, 2024 | Leerink Partners | Market Perform | Outperform | Upgrade |
Apr 02, 2024 | JMP Securities | - | Outperform | Upgrade |
Feb 13, 2024 | Leerink Partners | - | Market Perform | Downgrade |
Nov 14, 2022 | SVB Leerink | Outperform | Outperform | Hold |
AN2 Therapeutics Financial Forecast
AN2 Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
AN2 Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
AN2 Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-8.20M | $-7.75M | $-7.31M | $-7.01M | $-10.66M | $-13.42M | $-18.07M |
High Forecast | $-8.20M | $-7.75M | $-7.31M | $-7.01M | $-10.66M | $-11.61M | $-18.07M |
Low Forecast | $-8.20M | $-7.75M | $-7.31M | $-7.01M | $-10.66M | $-14.87M | $-18.07M |
Surprise % | - | - | - | - | - | - | - |
AN2 Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
AN2 Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.28 | $-0.26 | $-0.24 | $-0.23 | $-0.36 | $-0.45 | $-0.61 |
High Forecast | $-0.28 | $-0.26 | $-0.24 | $-0.23 | $-0.36 | $-0.39 | $-0.61 |
Low Forecast | $-0.28 | $-0.26 | $-0.24 | $-0.23 | $-0.36 | $-0.50 | $-0.61 |
Surprise % | - | - | - | - | - | - | - |
AN2 Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
ANTX Forecast FAQ
Is AN2 Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, AN2 Therapeutics (ANTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ANTX's total ratings.
What is ANTX's price target?
AN2 Therapeutics (ANTX) average price target is $8.75 with a range of $2 to $22, implying a 741.35% from its last price of $1.04. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AN2 Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ANTX stock, the company can go up by 741.35% (from the last price of $1.04 to the average price target of $8.75), up by 2015.38% based on the highest stock price target, and up by 92.31% based on the lowest stock price target.
Can AN2 Therapeutics stock reach $2?
ANTX's average twelve months analyst stock price target of $8.75 supports the claim that AN2 Therapeutics can reach $2 in the near future.
What are AN2 Therapeutics's analysts' financial forecasts?
AN2 Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.157M (high $-40.344M, low $-43.608M), average SG&A $0 (high $0, low $0), and average EPS is $-1.413 (high $-1.353, low $-1.462). ANTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.272M (high $-30.272M, low $-30.272M), average SG&A $0 (high $0, low $0), and average EPS is $-1.015 (high $-1.015, low $-1.015).